Vertex can’t quell uncertainty
Vertex Pharmaceuticals Inc. should be on top of the world. It’s drug to treat hepatitis C - years in development - became a virtual blockbuster as soon as it went on sale this year. The Cambridge company is also developing promising therapies to treat other diseases. But Vertex shares are sinking like a rock, down more than 36 percent since mid-September. Investors worry a new generation of other hepatitis C treatments - still in development - will overtake Vertex.